TY - JOUR
T1 - Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease
T2 - an international, expert RAND/UCLA appropriateness study
AU - Study of Upper Gastrointestinal Manifestations and Management of Crohn's Disease (SUMM-CD) Group
AU - Cohen, Nathaniel A.
AU - Bettenworth, Dominik
AU - Sror, Neta
AU - Khedraki, Raneem
AU - Yang, Qijun
AU - Abreu, Maria T.
AU - Atreya, Raja
AU - Al-Bawardy, Badr
AU - Connor, Susan J.
AU - D'Haens, Geert
AU - Dotan, Iris
AU - Dignass, Axel
AU - El Ouali, Sara
AU - Feagan, Brian
AU - Feakins, Roger
AU - Gearry, Richard
AU - Gordon, Ilyssa O.
AU - Hedin, Charlotte R.H.
AU - Hernandez-Rocha, Cristian
AU - Kobayashi, Taku
AU - Leibovitzh, Haim
AU - Lu, Cathy
AU - Maharshak, Nitsan
AU - Naseer, Maliha
AU - Ollech, Jacob
AU - Rubin, David T.
AU - Sebastian, Shaji
AU - Siegmund, Britta
AU - Silverberg, Mark S.
AU - Steinwurz, Flavio
AU - Torres, Joana
AU - Watermeyer, Gill
AU - Aswani Omprakash, Tina
AU - Frenkel, Lior
AU - Gurizzian, Paige
AU - Silfen, Alexa
AU - Tzadok, Roie
AU - Falloon, Katherine
AU - Rieder, Florian
N1 - Publisher Copyright:
Copyright © 2026 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
PY - 2026/3/1
Y1 - 2026/3/1
N2 - Patients with Crohn's disease can have isolated or co-existent upper gastrointestinal involvement, but this is an understudied clinical manifestation. There are neither standardised definitions nor diagnostic or management recommendations to help to guide clinical practice. Therefore, we conducted a RAND/University of California Los Angeles appropriateness study on the definition, diagnosis, management, and appropriate outcomes of upper gastrointestinal Crohn's disease (UGICD). An international expert panel of 30 gastroenterologists and pathologists and two patient representatives were recruited. Following a previously published systematic review, 1061 candidate items were grouped into questions and evaluated for appropriateness. Two modified Delphi rounds of voting with an interposed moderated group discussion were performed. The expert panel defined UGICD as disease occurring in the oesophagus, stomach, and/or duodenum (proximal to the ligament of Treitz) that can occur at any time during the disease course. Upper endoscopy is appropriate only in patients with newly diagnosed or existing Crohn's disease with suspicion for upper gastrointestinal involvement (eg, upper gastrointestinal symptoms or the presence of anaemia). Management of UGICD should be determined on a case-by-case basis and factors, such as disease location and symptomatic, endoscopic, and imaging severity, should guide medical, endoscopic, and surgical intervention. Both clinical and endoscopic response and remission are appropriate treatment targets for routine clinical practice; there is uncertainty about the value of histological outcomes in UGICD.
AB - Patients with Crohn's disease can have isolated or co-existent upper gastrointestinal involvement, but this is an understudied clinical manifestation. There are neither standardised definitions nor diagnostic or management recommendations to help to guide clinical practice. Therefore, we conducted a RAND/University of California Los Angeles appropriateness study on the definition, diagnosis, management, and appropriate outcomes of upper gastrointestinal Crohn's disease (UGICD). An international expert panel of 30 gastroenterologists and pathologists and two patient representatives were recruited. Following a previously published systematic review, 1061 candidate items were grouped into questions and evaluated for appropriateness. Two modified Delphi rounds of voting with an interposed moderated group discussion were performed. The expert panel defined UGICD as disease occurring in the oesophagus, stomach, and/or duodenum (proximal to the ligament of Treitz) that can occur at any time during the disease course. Upper endoscopy is appropriate only in patients with newly diagnosed or existing Crohn's disease with suspicion for upper gastrointestinal involvement (eg, upper gastrointestinal symptoms or the presence of anaemia). Management of UGICD should be determined on a case-by-case basis and factors, such as disease location and symptomatic, endoscopic, and imaging severity, should guide medical, endoscopic, and surgical intervention. Both clinical and endoscopic response and remission are appropriate treatment targets for routine clinical practice; there is uncertainty about the value of histological outcomes in UGICD.
UR - https://www.scopus.com/pages/publications/105030299801
U2 - 10.1016/S2468-1253(25)00347-4
DO - 10.1016/S2468-1253(25)00347-4
M3 - Review article
C2 - 41520669
AN - SCOPUS:105030299801
SN - 2468-1253
VL - 11
SP - 243
EP - 255
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
IS - 3
ER -